Enhancing Cancer Immunotherapy: A Novel Approach through the Integration of Oncolytic Virotherapy with CAR-T and NK Cell Therapies
DOI:
https://doi.org/10.62051/bxm5t423Keywords:
oncolytic virotherapy; CAR-T cell therapy; NK cell therapy; tumor microenvironment; immunotherapeutic effects; combination therapies.Abstract
A two-pronged approach to fighting cancer, oncolytic virotherapy (OV) combines direct tumor cytotoxicity with potentiation of anti-tumor immunity. Combining OVs and cell therapies, such as CAR-T and NK cells, has been proposed as an enhanced therapeutic approach. Additionally, it has been demonstrated that adding oncolytic virotherapy to combination medicines increases their therapeutic potential. This article explains the mechanisms underlying oncolytic viruses, the beneficial interactions between them and immune cell therapies, as well as the drawbacks and difficulties of this strategy. We highlight the novel approach of combining CAR T/NK cell treatments and oncolytic virotherapy, highlighting current developments and speculating on the future trajectories of this frontier in cancer immunotherapy.
Downloads
References
Guo, Zong Sheng, et al. “Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.” Biomedicines, U.S. National Library of Medicine, 10 July 2020, www.ncbi.nlm.nih.gov/pmc/articles/PMC7400484/.
Wang, Xianwang, et al. “Oncolytic Virotherapy Evolved into the Fourth Generation as Tumor Immunotherapy - Journal of Translational Medicine.” BioMed Central, BioMed Central, 25 July 2023, translational-medicine.biomedcentral.com/articles/10.1186/s12967 - 023 - 04360 - 8.
Liu, Shiyu, et al. “OX40L-Armed Oncolytic Virus Boosts T-Cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.” Theranostics, U.S. National Library of Medicine, 9 July 2023, www.ncbi.nlm.nih.gov/pmc/articles/PMC10405835/.
Chen, Pei-Hsuan, et al. “Activation of Car and Non-CAR T Cells within the Tumor Microenvironment Following Car T Cell Therapy.” JCI Insight, U.S. National Library of Medicine, 18 June 2020, www.ncbi.nlm.nih.gov/pmc/articles/PMC7406247/.
Sterner, Robert C., and Rosalie M. Sterner. “Car-T Cell Therapy: Current Limitations and Potential Strategies.” Nature News, Nature Publishing Group, 6 Apr. 2021, www.nature.com/articles/s41408-021-00459-.
Albinger, Nawid, et al. “Current Status and Perspective of Car-T and Car-NK Cell Therapy Trials in Germany.” Nature News, Nature Publishing Group, 22 Mar. 2021, www.nature.com/articles/s41434-021-00246-w.
Casucci, Monica, et al. “Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional Car-T Cells Co-Expressing a Suicide Gene.” Frontiers, Frontiers, 26 Feb. 2018, www.frontiersin.org/articles/10.3389/fimmu.2018.00507/full.
Carmen Campo “Effect of Age and CMV on NK Cell Subpopulations.” Experimental Gerontology, Pergamon, 17 Jan. 2014, www.sciencedirect.com/science/article/abs/pii/S0531556514000114.
Santos Apolonio, Jonathan, et al. “Oncolytic Virus Therapy in Cancer: A Current Review.” World Journal of Virology, U.S. National Library of Medicine, 25 Sept. 2021, www.ncbi.nlm.nih.gov/pmc/articles/PMC8474975/.
Guo, Zong Sheng, et al. “Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.” Biomedicines, U.S. National Library of Medicine, 10 July 2020, www.ncbi.nlm.nih.gov/pmc/articles/PMC7400484/.
Rojas, Juan J., et al. “Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.” American Association for Cancer Research, American Association for Cancer Research, 14 Dec. 2015, aacrjournals.org/clincancerres/article/21/24/5543/262914/Defining-Effective-Combinations-of-Immune.
Cronin, Michelle, et al. “Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.” Molecular Therapy, vol. 22, no. 6, 2014, pp. 1188 – 1197, https: //doi.org/10.1038/mt.2014. 23.
Gujar, Shashi A., and Patrick W. K. Lee. “Oncolytic Virus-Mediated Reversal of Impaired Tumor Antigen Presentation.” Frontiers, Frontiers, 27 Mar. 2014, www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2014.00077/full.
Jeffrey, Wojton, et al. “Impact of Tumor Microenvironment on Oncolytic Viral Therapy.” Cytokine & Growth Factor Reviews, Pergamon, 17 Apr. 2010, www.sciencedirect.com/science/article/abs/pii/S1359610110000250.
Guo, Zong Sheng, et al. “Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy.” Biomedicines, U.S. National Library of Medicine, 10 July 2020, www.ncbi.nlm.nih.gov/pmc/articles/PMC7400484/.
Maude, Shannon L, et al. “Managing Cytokine Release Syndrome Associated with Novel T Cell-Engaging Therapies.” Cancer Journal (Sudbury, Mass.), U.S. National Library of Medicine, 2014, www.ncbi.nlm.nih.gov/pmc/articles/PMC4119809/.
Maskalenko, Nicholas A., et al. “Harnessing Natural Killer Cells for Cancer Immunotherapy: Dispatching the First Responders.” Nature News, Nature Publishing Group, 21 Mar. 2022, www.nature.com/articles/s41573 - 022 - 00413 - 7.
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
